Can a single injection silence a clotting protein and prevent strokes?
NCT ID NCT05844293
First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time
Summary
This trial tests an experimental drug called FXI-GalNAc-siRNA, which uses RNA technology to temporarily lower a clotting protein in the blood. The goal is to see if a single injection is safe and how the body processes it in healthy adults aged 18 to 55. If it works, this approach might one day prevent dangerous blood clots with a lower risk of bleeding than standard blood thinners.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental RNA-based drug called FXI-GalNAc-siRNA that targets a clotting protein
- What this could lead to
- If successful, this could lead to a new way to prevent dangerous blood clots with fewer bleeding risks than current treatments.
- What could go wrong
- This is an early, small trial in healthy people, so it may not work as hoped or could have unexpected side effects. Results may not apply to patients with clotting disorders.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FXI are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
BioPharma
Creve Coeur, Missouri, 63141, United States
-
BioPharma
Toronto, Ontario, M9L 3A2, Canada